Oral creatine vs placebo
Adverse events related to treatment · children with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 40 participantsLow
Findings
What do systematic reviews say?
11 questions · 11 findings · 3 reviews · Headline outcomes only
No studies found 0 · 0%GRADE not reported 1 · 9.1%Very low 2 · 18.2%Low 3 · 27.3%Moderate 5 · 45.5%High 0 · 0%
Oral olesoxime vs placebo
Adverse events related to treatment · non‐ambulatory children and adolescents with SMA types II and III
Oral olesoxime probably leads to lower adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 0.95 [0.91, 0.99]1 study · 165 participantsModerate
Oral gabapentin vs placebo
Adverse events related to treatment · adults with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 65 participantsLow
Oral hydroxyurea vs placebo
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
- no estimate extracted1 study · 57 participantsModerate
Oral valproic acid vs placebo
Adverse events related to treatment · ambulatory adults with SMA type III
Oral valproic acid showed no clear difference in adverse events related to treatment compared with placebo (low certainty).
1 finding from 1 review
- RR 0.8 [0.44, 1.44]33 participantsLow
Oral phenylbutyrate vs placebo
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 3.1 [1.25, 7.84]1 study · 107 participantsModerate
Oral valproic acid plus acetyl‐L‐carnitine vs placebo
Adverse events related to treatment · non‐ambulatory children with SMA types II and III
Oral valproic acid plus acetyl‐L‐carnitine showed no clear difference in adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 1.32 [0.92, 1.89]1 study · 61 participantsModerate
Oral azithromycin vs placebo
Adverse events: number of mild treatment‐related adverse events · adults and children with cystic fibrosis
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extracted4 studies · 748 participantsModerate
Intramuscular ceftriaxone vs oral cefixime
Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection
1 finding from 1 review
- no estimate extracted1 study · 95 participantsGRADE not reported
Intramuscular ceftriaxone vs oral amoxicillin plus oral probenecid
Adverse events including treatment‐related adverse events · pregnant women with gonorrhoea infection
It is very uncertain whether intramuscular ceftriaxone changes adverse events including treatment‐related adverse events compared with oral amoxicillin plus oral probenecid (very low certainty).
1 finding from 1 review
- RR 0.33 [0.01, 8.07]1 study · 168 participantsVery low
Summary of findings ‐ nebulised azithromycin vs azithromycin
Adverse events: number of treatment‐related adverse events · children with cystic fibrosis
1 finding from 1 review
- Macrolide antibiotics (including azithromycin) for cystic fibrosis 2024 · Cochrane Headline outcomes onlyno estimate extracted1 study · 45 participantsVery low